1. Home
  2. ADPT vs BRZE Comparison

ADPT vs BRZE Comparison

Compare ADPT & BRZE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$14.81

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Logo Braze Inc.

BRZE

Braze Inc.

HOLD

Current Price

$23.68

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADPT
BRZE
Founded
2009
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
2.1B
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
ADPT
BRZE
Price
$14.81
$23.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
28
Target Price
$17.78
$38.04
AVG Volume (30 Days)
2.2M
2.9M
Earning Date
04-30-2026
03-24-2026
Dividend Yield
N/A
N/A
EPS Growth
63.89
N/A
EPS
N/A
N/A
Revenue
$276,976,000.00
$738,182,000.00
Revenue This Year
$3.98
$18.45
Revenue Next Year
$22.72
$16.54
P/E Ratio
N/A
N/A
Revenue Growth
54.77
24.40
52 Week Low
$6.71
$15.26
52 Week High
$20.76
$37.67

Technical Indicators

Market Signals
Indicator
ADPT
BRZE
Relative Strength Index (RSI) 53.80 64.25
Support Level $12.24 $23.28
Resistance Level $17.52 $29.50
Average True Range (ATR) 0.72 1.19
MACD 0.21 0.58
Stochastic Oscillator 97.21 91.65

Price Performance

Historical Comparison
ADPT
BRZE

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

About BRZE Braze Inc.

Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries. The company offers a single, vertically integrated platform that encompasses the various functionalities, or layers, required for modern customer engagement: data ingestion, classification, orchestration, personalization, and action, all of which is supported by Sage AI by Braze, its AI engine designed to power AI functionality across all layers of this stack. It generates majority of its revenue from the United States.

Share on Social Networks: